Factorial Biotechnologies
Private Company
Total funding raised: $24.5M
Overview
Founded in 2017, Factorial Biotechnologies is a private, platform-focused biotech company operating in the competitive field of therapeutic antibody discovery. The company leverages advanced high-throughput engineering and screening methods to streamline the traditionally slow and costly process of antibody development. While specific pipeline details are not publicly disclosed, its technology positions it to serve both internal program development and potential partnerships with larger biopharmaceutical companies. As a pre-revenue entity, its success hinges on validating its platform through compelling preclinical data and securing strategic collaborations or funding.
Technology Platform
High-throughput protein engineering platform combining synthetic DNA library generation, advanced cellular display or screening systems, automation, and data analytics/AI for therapeutic antibody discovery and optimization.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Factorial operates in a highly competitive field with numerous established players like AbCellera, Distributed Bio, and Adimab (for discovery platforms), and AI-driven companies like Absci and BigHat Biosciences. Its differentiation must be proven through head-to-head data on speed, library diversity, and the quality of output candidates. Success depends on demonstrating a unique and scalable technological edge.